Medera is one of China's leading developers and manufacturers of high-tech medical devices, as well as one of the world's leaders in medical device innovation. As of today, Myriad's market capitalization has reached $48.5 billion, much higher than Coleman Healthcare's $2.454 billion. In addition, Myriad Medical has already achieved its goal of global leadership in categories such as monitors, anesthesia machines and blood cells, while Komen Medical is mainly involved in six major areas, including electrophysiology monitoring, electrocardiology diagnosis, ultrasound maternal and infant monitoring, respiratory anesthesia, infant care and operating room equipment.
In terms of business scope, Myriad Medical has a wider range of business involving a variety of medical devices. In contrast, Coman Medical mainly focuses on the monitoring product line. In addition, Myriad Healthcare has provided medical technologies, products, services and integrated solutions to more than 50,000 medical institutions and social service and security organizations globally, while Komen Healthcare provides services to 50,000 medical institutions and social service and security organizations in more than 130 countries and regions worldwide.
In summary, Myriad Healthcare has an advantage in terms of market capitalization, business scope and degree of internationalization, and therefore has greater potential.